RxDoctor Payments DataLook up a doctor →

J Cal Noorda, MD

Internal Medicine · North Las Vegas, NVNPI 1073586087

Payments from drug & device makers

$15,461in general payments, 2019–2025

Across 812 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • AbbVie$2K
  • GSK$927
  • Boehringer Ingelheim$849
  • Amgen$770
  • plus $7K from 44 others

What the payments were for

  • Food & beverage$15,28999%
  • Education$1261%
  • Other$460%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,461 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$66,673
Medicare patients
282
Services billed
910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$94,115
TrulicityDulaglutide34$64,045
RybelsusSemaglutide35$62,939
JardianceEmpagliflozin36$55,089
OzempicSemaglutide28$46,912
MounjaroTirzepatide23$34,999
JanuviaSitagliptin Phosphate18$28,415
XareltoRivaroxaban18$18,033
FarxigaDapagliflozin Propanediol12$14,208
MyrbetriqMirabegron14$13,650
Atorvastatin Calcium502$5,100
Losartan Potassium274$3,385
Levothyroxine Sodium267$3,195
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,160
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,929$109,85163 claims
Lilly USA, LLCTrulicity, Mounjaro$699$99,04357 claims
PfizerEliquis$688$94,11584 claims
Boehringer IngelheimJardiance$849$55,08936 claims
MerckJanuvia$136$28,41518 claims
Johnson & JohnsonXarelto$463$18,03318 claims
AstraZenecaFarxiga$1,869$14,20812 claims
Astellas Pharma US IncMyrbetriq$592$13,65014 claims
AbbVieSynthroid$1,816$2,05459 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in North Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →